Inhibition of TGFβ signaling and its implications in anticancer treatments
The transforming growth factor-β (TGFβ) is a potent regulator of tumorigenesis. In cancer, two distinctive behaviors of TGFβ have been reported as a tumor suppressor at early stage of the disease, and as a tumor promoter at later stages. The past decades, the dualistic role of TGFβ has garnered a lo...
Збережено в:
| Опубліковано в: : | Experimental Oncology |
|---|---|
| Дата: | 2012 |
| Автори: | , |
| Формат: | Стаття |
| Мова: | Англійська |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2012
|
| Теми: | |
| Онлайн доступ: | https://nasplib.isofts.kiev.ua/handle/123456789/138683 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Inhibition of TGFβ signaling and its implications in anticancer treatments / I. Calone, S. Souchelnytskyi // Experimental Oncology. — 2012. — Т. 34, № 1. — С. 9-16. — Бібліогр.: 95 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| _version_ | 1862731430653591552 |
|---|---|
| author | Calone, I. Souchelnytskyi, S. |
| author_facet | Calone, I. Souchelnytskyi, S. |
| citation_txt | Inhibition of TGFβ signaling and its implications in anticancer treatments / I. Calone, S. Souchelnytskyi // Experimental Oncology. — 2012. — Т. 34, № 1. — С. 9-16. — Бібліогр.: 95 назв. — англ. |
| collection | DSpace DC |
| container_title | Experimental Oncology |
| description | The transforming growth factor-β (TGFβ) is a potent regulator of tumorigenesis. In cancer, two distinctive behaviors of TGFβ have been reported as a tumor suppressor at early stage of the disease, and as a tumor promoter at later stages. The past decades, the dualistic role of TGFβ has garnered a lot of attention. As a result, cancer researchers’ has been tasked to elucidate how TGFβ signaling may lead to metastatic dissemination, how to tackle carcinogenesis and which therapeutic strategies should be adopted. Consequently, TGFβ signaling pathways have been considered as appropriate targets for cancer therapy. The TGFβ therapeutic strategies have emerged at three levels: ligand, ligand-receptor interaction and intracellular signaling level. Promising inhibitors of TGFβ signaling have entered clinical trials and shown encouraging results. Here we review the three strategies of TGFβ signaling inhibition and theirs applications in treatment of cancer.
|
| first_indexed | 2025-12-07T19:26:13Z |
| format | Article |
| fulltext | |
| id | nasplib_isofts_kiev_ua-123456789-138683 |
| institution | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| issn | 1812-9269 |
| language | English |
| last_indexed | 2025-12-07T19:26:13Z |
| publishDate | 2012 |
| publisher | Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| record_format | dspace |
| spelling | Calone, I. Souchelnytskyi, S. 2018-06-19T11:37:07Z 2018-06-19T11:37:07Z 2012 Inhibition of TGFβ signaling and its implications in anticancer treatments / I. Calone, S. Souchelnytskyi // Experimental Oncology. — 2012. — Т. 34, № 1. — С. 9-16. — Бібліогр.: 95 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/138683 The transforming growth factor-β (TGFβ) is a potent regulator of tumorigenesis. In cancer, two distinctive behaviors of TGFβ have been reported as a tumor suppressor at early stage of the disease, and as a tumor promoter at later stages. The past decades, the dualistic role of TGFβ has garnered a lot of attention. As a result, cancer researchers’ has been tasked to elucidate how TGFβ signaling may lead to metastatic dissemination, how to tackle carcinogenesis and which therapeutic strategies should be adopted. Consequently, TGFβ signaling pathways have been considered as appropriate targets for cancer therapy. The TGFβ therapeutic strategies have emerged at three levels: ligand, ligand-receptor interaction and intracellular signaling level. Promising inhibitors of TGFβ signaling have entered clinical trials and shown encouraging results. Here we review the three strategies of TGFβ signaling inhibition and theirs applications in treatment of cancer. Projects in the Souchelnytskyi group are supported by the Karolinska Biomics Center, the Karolinska Institute, the Swedish Research Council, the Swedish Institute, the Swedish Cancer Foundation, the EuroCanPlatform initiative, the King Gustav V Jubilee Fund, and the Ludwig institute for Cancer Research to S.S. en Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України Experimental Oncology Reviews Inhibition of TGFβ signaling and its implications in anticancer treatments Article published earlier |
| spellingShingle | Inhibition of TGFβ signaling and its implications in anticancer treatments Calone, I. Souchelnytskyi, S. Reviews |
| title | Inhibition of TGFβ signaling and its implications in anticancer treatments |
| title_full | Inhibition of TGFβ signaling and its implications in anticancer treatments |
| title_fullStr | Inhibition of TGFβ signaling and its implications in anticancer treatments |
| title_full_unstemmed | Inhibition of TGFβ signaling and its implications in anticancer treatments |
| title_short | Inhibition of TGFβ signaling and its implications in anticancer treatments |
| title_sort | inhibition of tgfβ signaling and its implications in anticancer treatments |
| topic | Reviews |
| topic_facet | Reviews |
| url | https://nasplib.isofts.kiev.ua/handle/123456789/138683 |
| work_keys_str_mv | AT calonei inhibitionoftgfβsignalinganditsimplicationsinanticancertreatments AT souchelnytskyis inhibitionoftgfβsignalinganditsimplicationsinanticancertreatments |